Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 4/2017

01-04-2017 | Original Research Article

A Retrospective Cohort Study of Acute Kidney Injury Risk Associated with Antipsychotics

Authors: Yawen Jiang, Jeffrey S. McCombs, Susie H. Park

Published in: CNS Drugs | Issue 4/2017

Login to get access

Abstract

Background

A recent large database analysis raised concerns of potential acute kidney injury (AKI) risk associated with antipsychotics. However, whether individual atypical and typical antipsychotics are associated with differential AKI risks has not been investigated.

Objective

The current study compared the risks of AKI and known causes of AKI associated with a broad range of atypical and typical antipsychotics.

Method

This retrospective cohort analysis used January 2007–June 2013 US nationwide Humana claims data to define episodes of antipsychotic drug therapy for patients with schizophrenia and bipolar disorder. Study drugs were aripiprazole, fluphenazine, haloperidol, olanzapine, quetiapine, risperidone, and ziprasidone. Study outcomes were hospitalizations with AKI, and known causes of AKI, i.e., hypotension, acute urinary retention, neuroleptic malignant syndrome/rhabdomyolysis, and pneumonia. AKI was the primary outcome of the study. Cox regressions using haloperidol as the baseline comparator were used to estimate the impact of alternative antipsychotics on the risks of study adverse events following the initiation of treatment. The Cox models controlled for treatment history, comorbidities, and concomitant drug use in the prior 6 months. They also controlled for patient demographics and dose of current treatment.

Results

The overall incidence of AKI was 25.0 per 1000 person-years. According to our multivariate regression results, the risk of AKI was significantly increased in patients taking olanzapine [hazard ratio (HR) 1.344, 95% confidence interval (CI) 1.057–1.708], quetiapine (HR 1.350, 95% CI 1.082–1.685), and ziprasidone (HR 1.338, 95% CI 1.035–1.729) relative to haloperidol. Aripiprazole (HR 1.152, 95% CI 0.908–1.462) and risperidone (HR 1.147, 95% CI 0.923–1.426) had insignificantly higher risks of AKI compared with haloperidol, whereas fluphenazine (HR 0.729, 95% CI 0.483–1.102) had an insignificantly lower risk of AKI. When compared between drug classes, atypical antipsychotics had a significantly higher risk of AKI (HR 1.313, 95% CI 1.083–1.591) than typical antipsychotics.

Conclusions

Antipsychotics are associated with differential AKI risks, with several atypical antipsychotics having higher risks than haloperidol. However, the overall incidence of AKI was moderate, and AKI risk should only raise concern for clinicians with elderly patients or patients who are vulnerable to kidney disease.
Appendix
Available only for authorised users
Literature
1.
2.
Huskamp HA, O’Malley AJ, Horvitz-Lennon M, Taub AL, Berndt ER, Donohue JM. How quickly do physicians adopt new drugs? The case of second-generation antipsychotics. Psychiatr Serv. 2013;64(4):324–30.CrossRefPubMedPubMedCentral
3.
Joshi K, Lin J, Lingohr-Smith M, Fu D-J, Muser E. treatment patterns and antipsychotic medication adherence among commercially insured patients with schizoaffective disorder in the United States. J Clin Psychopharmacol. 2016;36(5):429.CrossRefPubMedPubMedCentral
4.
Donohue J, O’Malley AJ, Horvitz-Lennon M, Taub AL, Berndt ER, Huskamp HA. Changes in physician antipsychotic prescribing preferences, 2002–2007. Psychiatr Serv. 2014;65(3):315–22.CrossRefPubMedPubMedCentral
5.
Gonzalez JM, Thompson PM, Moore TA. Review of the safety, efficacy, and side effect profile of asenapine in the treatment of bipolar 1 disorder. Patient Prefer Adher. 2011;5:333.CrossRef
6.
Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry. 2006;51(8):480–91.CrossRefPubMed
7.
Jiang Y, Ni W. Health care utilization and treatment persistence associated with oral paliperidone and lurasidone in schizophrenia treatment. J Manag Care Spec Pharm. 2015;21(9):780–92.CrossRefPubMed
8.
Jiang Y, Ni W. Estimating the impact of adherence to and persistence with atypical antipsychotic therapy on health care costs and risk of hospitalization. Pharmacother J Hum Pharmacol Drug Therapy. 2015;35(9):813–22.CrossRef
9.
Knapp M, King D, Pugner K, Lapuerta P. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry. 2004;184(6):509–16.CrossRefPubMed
10.
Hwang YJ, Dixon SN, Reiss JP, Wald R, Parikh CR, Gandhi S, et al. Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults. A population-based cohort study. Ann Intern Med. 2014;161(4):242–8.CrossRefPubMed
11.
Kirkham J, Seitz D. New use of antipsychotics associated with a small increased risk of acute kidney injury in older adults with mental disorders. Evid Based Mental Health. 2015;18(2):55.CrossRef
12.
Weiden PJ. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv (Washington, DC). 2004;55(8):886–91.CrossRef
13.
Chen L, McCombs JS, Park J. The impact of atypical antipsychotic medications on the use of health care by patients with schizophrenia. Value Health. 2008;11(1):34–43.CrossRefPubMed
14.
Horvitz-Lennon M, Donohue JM, Lave JR, Alegria M, Normand SL. The effect of race-ethnicity on the comparative effectiveness of clozapine among Medicaid beneficiaries. Psychiatr Serv. 2013;64(3):230–7.CrossRefPubMedPubMedCentral
15.
Hansen RA, Dusetzina SB, Dominik RC, Gaynes BN. Prescription refill records as a screening tool to identify antidepressant non-adherence. Pharmacoepidemiol Drug Saf. 2010;19(1):33–7.CrossRefPubMedPubMedCentral
16.
Waikar SS, Wald R, Chertow GM, Curhan GC, Winkelmayer WC, Liangos O, et al. Validity of international classification of diseases, ninth revision, clinical modification codes for acute renal failure. J Am Soc Nephrol. 2006;17(6):1688–94.CrossRefPubMed
17.
Hasnain M, Vieweg WVR. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. CNS Drugs. 2014;28(10):887–920.CrossRefPubMed
18.
Gugger JJ. Antipsychotic pharmacotherapy and orthostatic hypotension. CNS Drugs. 2011;25(8):659–71.CrossRefPubMed
19.
Chiang C-L, Liu C-C. Micturition difficulty associated with aripiprazole: report of 2 cases. J Clin Psychopharmacol. 2011;31(1):128–9.CrossRefPubMed
20.
Parekh R, Fattah Z, Sahota D, Colaco B. Clozapine induced tubulointerstitial nephritis in a patient with paranoid schizophrenia. BMJ Case Rep. 2014;2014:bcr2013203502.
21.
Belvederi Murri M, Guaglianone A, Bugliani M, Calcagno P, Respino M, Serafini G, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs R D. 2015;15(1):45–62.CrossRefPubMedPubMedCentral
22.
Nose M, Recla E, Trifiro G, Barbui C. Antipsychotic drug exposure and risk of pneumonia: a systematic review and meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2015;24(8):812–20.CrossRefPubMed
23.
Satagopan J, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach A. A note on competing risks in survival data analysis. Br J Cancer. 2004;91(7):1229–35.CrossRefPubMedPubMedCentral
24.
Jackson D, White IR, Seaman S, Evans H, Baisley K, Carpenter J. Relaxing the independent censoring assumption in the Cox proportional hazards model using multiple imputation. Stat Med. 2014;33(27):4681–94.CrossRefPubMedPubMedCentral
25.
Greene WH. Econometric analysis. 7th ed. Upper Saddle River: Pearson Education, Inc.; 2012.
26.
Cameron AC, Trivedi PK. Microeconometrics: methods and applications. New York: Cambridge University Press; 2005.CrossRef
27.
Gardner DM, Murphy AL, O’Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. AJ Psychiatry. 2010;167(6):686–93.
28.
Mortimer AM. Atypical Antipsychotics as first-line treatments for schizophrenia. Dis Manag Health Out. 2004;12(3):169–79.CrossRef
29.
Gentile S. Atypical antipsychotics for the treatment of bipolar disorder: more shadows than lights. CNS Drugs. 2007;21(5):367–87.CrossRefPubMed
30.
Terza JV, Basu A, Rathouz PJ. Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling. J Health Econ. 2008;27(3):531–43.CrossRefPubMed
31.
Nardi A, Schemper M. Comparing Cox and parametric models in clinical studies. Stat Med. 2003;22(23):3597–610.CrossRefPubMed
32.
Noordzij M, Leffondré K, van Stralen KJ, Zoccali C, Dekker FW, Jager KJ. When do we need competing risks methods for survival analysis in nephrology? Nephrol Dial Transpl. 2013;28(11):2670–7.CrossRef
33.
Bowry SK, Schoder V, Apel C. An inadvertent but explicable error in calculating number needed to treat for reporting survival data. J Am Soc Nephrol. 2014;25(5):875–6.CrossRefPubMedPubMedCentral
34.
Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915–20.CrossRefPubMed
35.
Gianfrancesco F, Pesa J, Wang R-H, Nasrallah H. Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: sensitivity to study design. Am J Health Syst Pharm. 2006;63(5):431–41.CrossRefPubMed
36.
Johnson ES, Bartman BA, Briesacher BA, Fleming NS, Gerhard T, Kornegay CJ, et al. The incident user design in comparative effectiveness research. Pharmacoepidemiol Drug Saf. 2013;22(1):1–6.CrossRefPubMed
37.
Moledina DG, Perazella MA. Acute kidney injury and mortality in the elderly: add atypical antipsychotics to the list. Am J Kidney Dis. 2015;65(5):655–8.CrossRefPubMed
38.
He L, Peng Y, Fu X, Chen X, Liu H. Dibenzodiazepine derivative quetiapine-and olanzapine-induced chronic interstitial nephritis. Ren Fail. 2013;35(5):657–9.CrossRefPubMed
39.
Gulec M, Ozcan H, Oral E, Dursun OB, Unal D, Aksak S, et al. Nephrotoxic effects of chronically administered olanzapine and risperidone in male rats. Klinik Psikofarmakoloji Bülteni Bull Clin Psychopharmacol. 2012;22(2):139–47.CrossRef
Metadata
Title
A Retrospective Cohort Study of Acute Kidney Injury Risk Associated with Antipsychotics
Authors
Yawen Jiang
Jeffrey S. McCombs
Susie H. Park
Publication date
01-04-2017
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 4/2017
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.1007/s40263-017-0421-4

Other articles of this Issue 4/2017

CNS Drugs 4/2017 Go to the issue

Original Research Article

Newer Antiepileptic Drugs in Status Epilepticus: Prescription Trends and Outcomes in Comparison with Traditional Agents

Review article

Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis

Systematic Review

Statin Adherence and the Risk of Stroke: A Dose-Response Meta-Analysis

Review Article

Pharmacotherapy in Generalized Anxiety Disorder: Novel Experimental Medicine Models and Emerging Drug Targets

Review Article

Dosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial Data

Leading Article

Potential Use of MicroRNA for Monitoring Therapeutic Response to Antidepressants